Literature DB >> 32989457

Serotype Patterns of Pneumococcal Disease in Adults Are Correlated With Carriage Patterns in Older Children.

Anne L Wyllie1, Joshua L Warren2, Gili Regev-Yochay3,4,5, Noga Givon-Lavi6, Ron Dagan6, Daniel M Weinberger1.   

Abstract

BACKGROUND: The importance of specific serotypes causing invasive pneumococcal disease (IPD) differs by age. Data on pneumococcal carriage in different age groups, along with data on serotype-specific invasiveness, could help explain these age-related patterns and their implications for vaccination.
METHODS: Using pneumococcal carriage and disease data from Israel, we evaluated the association between serotype-specific IPD in adults and serotype-specific carriage prevalence among children in different age categories, while adjusting for serotype-specific invasiveness. We estimated carriage prevalence using different age groupings that were selected a priori. The Deviance Information Criterion was used to determine which age groupings of carriage data best fit the adult IPD data. Serotype-specific disease patterns were further evaluated by stratifying IPD data by comorbidity status.
RESULTS: The relative frequency of serotypes causing IPD differed between adults and children, and also differed between older and younger adults and between adults with and without comorbidities. Serotypes overrepresented as causes of IPD in adults were more commonly carried in older children compared with younger children. In line with this, the serotype-specific frequency of carriage in older children, rather than infants, best correlated with serotype-specific IPD in adults.
CONCLUSIONS: These analyses demonstrate that the serotype patterns in carriage in older children, rather than infants, are best correlated with disease patterns in adults. This might suggest these older children are more influential for disease patterns in adults. These insights could help in optimizing vaccination strategies to reduce disease burden across all ages.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  pneumococcus; comorbidity; disease prediction; elderly; invasive pneumococcal disease

Mesh:

Substances:

Year:  2021        PMID: 32989457      PMCID: PMC8315131          DOI: 10.1093/cid/ciaa1480

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  32 in total

1.  Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children.

Authors:  Angela B Brueggemann; Timothy E A Peto; Derrick W Crook; Jay C Butler; Karl G Kristinsson; Brian G Spratt
Journal:  J Infect Dis       Date:  2004-08-25       Impact factor: 5.226

2.  The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.

Authors:  Gili Regev-Yochay; Michal Katzir; Jacob Strahilevitz; Galia Rahav; Talya Finn; Dan Miron; Yasmin Maor; Bibiana Chazan; Yehudith Schindler; Ron Dagan
Journal:  Vaccine       Date:  2017-03-22       Impact factor: 3.641

3.  Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities.

Authors:  Jennifer R Scott; Eugene V Millar; Marc Lipsitch; Lawrence H Moulton; Robert Weatherholtz; Mindy J Perilla; Delois M Jackson; Bernard Beall; Mariddie J Craig; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  J Infect Dis       Date:  2011-11-29       Impact factor: 5.226

Review 4.  Epidemiological differences among pneumococcal serotypes.

Authors:  William P Hausdorff; Daniel R Feikin; Keith P Klugman
Journal:  Lancet Infect Dis       Date:  2005-02       Impact factor: 25.071

5.  Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands.

Authors:  Gertjan H J Wagenvoort; Elisabeth A M Sanders; Bart J Vlaminckx; Karin E Elberse; Hester E de Melker; Arie van der Ende; Mirjam J Knol
Journal:  Vaccine       Date:  2016-01-08       Impact factor: 3.641

6.  Density, Serotype Diversity, and Fitness of Streptococcus pneumoniae in Upper Respiratory Tract Cocolonization With Nontypeable Haemophilus influenzae.

Authors:  Joseph A Lewnard; Amit Huppert; Noga Givon-Lavi; Melinda M Pettigrew; Gili Regev-Yochay; Ron Dagan; Daniel M Weinberger
Journal:  J Infect Dis       Date:  2016-08-17       Impact factor: 5.226

7.  Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR).

Authors:  Rania Abu Seir; Kifaya Azmi; Ayob Hamdan; Hanan Namouz; Fuad Jaar; Hanaa Jaber; Carmit Rubin; Dafna Doron; Galia Rahav; Ziad Abdeen; Gili Regev-Yochay
Journal:  PLoS One       Date:  2018-11-12       Impact factor: 3.240

8.  Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands.

Authors:  Anna M M van Deursen; Suzan P van Mens; Elisabeth A M Sanders; Bart J M Vlaminckx; Hester E de Melker; Leo M Schouls; Sabine C de Greeff; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

9.  Pneumococcal transmission and disease in silico: a microsimulation model of the indirect effects of vaccination.

Authors:  Markku Nurhonen; Allen C Cheng; Kari Auranen
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study.

Authors:  Stefan Flasche; Marc Lipsitch; John Ojal; Amy Pinsent
Journal:  BMC Med       Date:  2020-06-10       Impact factor: 11.150

View more
  5 in total

Review 1.  Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change.

Authors:  Tamas Fulop; Anis Larbi; Graham Pawelec; Alan A Cohen; Guillaume Provost; Abedelouahed Khalil; Guy Lacombe; Serafim Rodrigues; Mathieu Desroches; Katsuiku Hirokawa; Claudio Franceschi; Jacek M Witkowski
Journal:  Vaccines (Basel)       Date:  2022-04-13

2.  It Takes Two to Tango: Combining Conventional Culture With Molecular Diagnostics Enhances Accuracy of Streptococcus pneumoniae Detection and Pneumococcal Serogroup/Serotype Determination in Carriage.

Authors:  Willem R Miellet; Janieke van Veldhuizen; David Litt; Rob Mariman; Alienke J Wijmenga-Monsuur; Paul Badoux; Tessa Nieuwenhuijsen; Rebecca Thombre; Sanaa Mayet; Seyi Eletu; Carmen Sheppard; Marianne Alice van Houten; Nynke Y Rots; Elizabeth Miller; Norman K Fry; Elisabeth A M Sanders; Krzysztof Trzciński
Journal:  Front Microbiol       Date:  2022-04-18       Impact factor: 6.064

3.  Pneumococcal genetic variability in age-dependent bacterial carriage.

Authors:  Philip H C Kremer; Bart Ferwerda; Hester J Bootsma; Nienke Y Rots; Alienke J Wijmenga-Monsuur; Elisabeth A M Sanders; Krzysztof Trzciński; Anne L Wyllie; Paul Turner; Arie van der Ende; Matthijs C Brouwer; Stephen D Bentley; Diederik van de Beek; John A Lees
Journal:  Elife       Date:  2022-07-26       Impact factor: 8.713

4.  Characterization of Emerging Serotype 19A Pneumococcal Strains in Invasive Disease and Carriage, Belgium.

Authors:  Stefanie Desmet; Heidi Theeten; Lies Laenen; Lize Cuypers; Piet Maes; Wouter Bossuyt; Liesbet Van Heirstraeten; Willy E Peetermans; Katrien Lagrou
Journal:  Emerg Infect Dis       Date:  2022-08       Impact factor: 16.126

5.  Estimating the contribution of HIV-infected adults to household pneumococcal transmission in South Africa, 2016-2018: A hidden Markov modelling study.

Authors:  Deus Thindwa; Nicole Wolter; Amy Pinsent; Maimuna Carrim; John Ojal; Stefano Tempia; Jocelyn Moyes; Meredith McMorrow; Jackie Kleynhans; Anne von Gottberg; Neil French; Cheryl Cohen; Stefan Flasche
Journal:  PLoS Comput Biol       Date:  2021-12-23       Impact factor: 4.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.